Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility

Seattle, April 30 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA® (pegloticase injection) – a biologic medicine for treatment of chronic gout refractory to conventional therapies (uncontrolled gout), at its [...]